Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineDaniel D. Von Hoff, Markus F. Renschler, Scot Dowden et al.|New England Journal of Medicine|2013Cited by 6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesChetan Bettegowda, Jon Weingart, Mark Sausen et al.|Science Translational Medicine|2014Cited by 5.1k
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic CancerThomas B. Karasic, Peter J. O’Dwyer, Mark H. O’Hara et al.|JAMA Oncology|2019Cited by 289
Metastatic Pancreatic Cancer: ASCO Guideline UpdateDavendra Sohal, Daniel A. Laheru, Erin B. Kennedy et al.|Journal of Clinical Oncology|2020Cited by 287
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinomaAna De Jesus‐Acosta, Daniel A. Laheru|British Journal of Cancer|2019Cited by 163